{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:09:38Z","timestamp":1790838578640,"version":"4.1.0"},"reference-count":121,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disorder caused by degeneration of dopaminergic neurons and accumulation of \u03b1-synuclein protein, leading to sustained neuroinflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review analyze the application of gene silencing mediated by small interfering RNAs for \u03b1-synuclein protein and inflammatory factors in the treatment of PD. The use of exosomes-mimetic nanoparticles (EM-NPs) for siRNA delivery will be highlighted in particular.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review highlights recent findings on the molecular mechanisms involved in PD, the development of siRNA drugs, and the potential of EM-NP-mediated siRNA delivery systems for CNS delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>siRNA provides an excellent approach to silence specific disease-related genes, such as SNCA and inflammatory factors. Nevertheless, its practical application is hampered by low stability, enzymatic degradation, difficulty crossing the BBB, and non-specific activity. EM-NPs combine the advantages of biocompatibility and scalability that natural exosomes possess and synthetic nanoparticles exhibit, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The delivery of siRNA molecules via EM-NPs could be considered an innovative disease-modifying approach toward treating PD patients, involving both pathological \u03b1-synuclein protein and neuroinflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgag052","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:22:09Z","timestamp":1777638129000},"source":"Crossref","is-referenced-by-count":2,"title":["Exosome mimetic nanoparticles for siRNA based targeting of \u03b1-synuclein and neuroinflammation in Parkinson\u2019s disease"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6103-1243","authenticated-orcid":false,"given":"Shamim","family":"Shamim","sequence":"first","affiliation":[{"name":"Department of Pharmacy, IIMT University , Ganga Nagar, Meerut, Uttar Pradesh 250001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8868-8676","authenticated-orcid":false,"given":"Atul Pratap","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, IIMT University , Ganga Nagar, Meerut, Uttar Pradesh 250001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7608-1933","authenticated-orcid":false,"given":"Himanchal","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, IIMT University , Ganga Nagar, Meerut, Uttar Pradesh 250001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6981-2140","authenticated-orcid":false,"given":"Smriti","family":"Gohri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, IIMT University , Ganga Nagar, Meerut, Uttar Pradesh 250001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8967-4672","authenticated-orcid":false,"given":"Dhananjay","family":"Taumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, IIMT University , Ganga Nagar, Meerut, Uttar Pradesh 250001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3572-4748","authenticated-orcid":false,"given":"Vatan","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, IIMT University , Ganga Nagar, Meerut, Uttar Pradesh 250001 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2026060313352420500_ref1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40478-022-01327-6","article-title":"Ischemic stroke causes Parkinson\u2019s disease-like pathology and symptoms in transgenic mice overexpressing alpha-synuclein","volume":"10","author":"Lohmann","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"2026060313352420500_ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.736978","article-title":"Alpha-synuclein aggregation in Parkinson\u2019s disease","volume":"8","author":"Srinivasan","year":"2021","journal-title":"Front Med"},{"key":"2026060313352420500_ref3","doi-asserted-by":"publisher","first-page":"167930","DOI":"10.1016\/j.jmb.2022.167930","article-title":"The hidden cell-to-cell trail of \u03b1-synuclein aggregates","volume":"435","author":"Neupane","year":"2023","journal-title":"J Mol Biol"},{"key":"2026060313352420500_ref4","doi-asserted-by":"publisher","first-page":"109129","DOI":"10.1016\/j.bioorg.2025.109129","article-title":"Therapeutic innovation through drug repurposing: a multidimensional approach toward treating Parkinson\u2019s disease","volume":"166","author":"Sahoo","year":"2025","journal-title":"Bioorg Chem"},{"key":"2026060313352420500_ref5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","article-title":"Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression","volume":"132","author":"Riederer","year":"2025","journal-title":"J Neural Transm"},{"key":"2026060313352420500_ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpx.2026.100503","article-title":"Brain-targeted delivery of siRNA via non-viral delivery systems, the therapeutic strategy for Alzheimer\u2019s disease\u2014unveiling challenges and prospects","volume":"11","author":"Gu","year":"2026","journal-title":"Int J Pharm X"},{"key":"2026060313352420500_ref7","doi-asserted-by":"publisher","first-page":"100129","DOI":"10.1016\/j.nxnano.2024.100129","article-title":"Nanomedicine: how nanomaterials are transforming drug delivery, bio-imaging, and diagnosis","volume":"7","author":"Kurul","year":"2025","journal-title":"Next Nanotechnol"},{"key":"2026060313352420500_ref8","doi-asserted-by":"publisher","first-page":"125186","DOI":"10.1016\/j.ijpharm.2025.125186","article-title":"Advancing neurological disorders therapies: organic nanoparticles as a key to blood-brain barrier penetration","volume":"670","author":"Sadat Razavi","year":"2025","journal-title":"Int J Pharm"},{"key":"2026060313352420500_ref9","doi-asserted-by":"publisher","first-page":"100233","DOI":"10.1016\/j.nxnano.2025.100233","article-title":"Nanomedicine breakthroughs in cancer and neurodegenerative disease therapy","volume":"8","author":"Haque","year":"2025","journal-title":"Next Nanotechnol"},{"key":"2026060313352420500_ref10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/neurolint16030037","article-title":"Oxidative stress and neurodegeneration: insights and therapeutic strategies for Parkinson\u2019s disease","volume":"16","author":"Bej","year":"2024","journal-title":"Neurol Int"},{"key":"2026060313352420500_ref11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10571-025-01544-2","article-title":"Alpha-synuclein pathophysiology in neurodegenerative disorders: a review focusing on molecular mechanisms and treatment advances in Parkinson\u2019s disease","volume":"45","author":"Yaribash","year":"2025","journal-title":"Cell Mol Neurobiol"},{"key":"2026060313352420500_ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cells12071012","volume-title":"Microglia Mediated Neuroinflammation in Parkinson\u2019s Disease","author":"Isik","year":"2023"},{"key":"2026060313352420500_ref13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.trsl.2022.08.006","article-title":"NLRP3 inflammasome in neurodegenerative disease","volume":"252","author":"Anderson","year":"2023","journal-title":"Transl Res"},{"key":"2026060313352420500_ref14","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/bph.15414","article-title":"Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy","volume":"178","author":"Monty","year":"2021","journal-title":"Br J Pharmacol"},{"key":"2026060313352420500_ref15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3390\/mi14071321","article-title":"Basic principles of RNA interference: nucleic acid types and in vitro intracellular delivery methods","volume":"14","author":"Isenmann","year":"2023","journal-title":"Micromachines"},{"key":"2026060313352420500_ref16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13287-023-03275-x","article-title":"Engineering exosomes and biomaterial-assisted exosomes as therapeutic carriers for bone regeneration","volume":"14","author":"Lu","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"2026060313352420500_ref17","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cells11111732","article-title":"Alpha-synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches","volume":"11","author":"Vidovi\u0107","year":"2022","journal-title":"Cells"},{"key":"2026060313352420500_ref18","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/pharmaceutics17091169","article-title":"Cracking the blood\u2013brain barrier code: rational nanomaterial design for next-generation neurological therapies","volume":"17","author":"N\u00e1jera-Maldonado","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for siRNA therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"key":"2026060313352420500_ref20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bph.17302","article-title":"Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence","volume":"182","author":"Bereczki","year":"2025","journal-title":"Br J Pharmacol"},{"key":"2026060313352420500_ref21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/pharmaceutics14050908","article-title":"Exosomes derived from dental pulp stem cells show different angiogenic and osteogenic properties in relation to the age of the donor","volume":"14","author":"Brunello","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4274\/balkanmedj.galenos.2022.2022-7-100","article-title":"Neuroinflammation in Parkinson\u2019s disease and its treatment opportunities","volume":"39","author":"\u00c7\u0131nar","year":"2022","journal-title":"Balkan Med J"},{"key":"2026060313352420500_ref23","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ymthe.2022.10.008","article-title":"Cell-derived nanovesicle-mediated drug delivery to the brain: principles and strategies for vesicle engineering","volume":"31","author":"Liang","year":"2023","journal-title":"Mol Ther"},{"key":"2026060313352420500_ref24","doi-asserted-by":"publisher","first-page":"124786","DOI":"10.1016\/j.ijpharm.2024.124786","article-title":"Nanotechnology used for siRNA delivery for the treatment of neurodegenerative diseases: focusing on Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"666","author":"Li","year":"2024","journal-title":"Int J Pharm"},{"key":"2026060313352420500_ref25","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1007\/s12035-025-04825-5","article-title":"Exosomes as biomarkers and therapeutic agents in neurodegenerative diseases: current insights and future directions","volume":"62","author":"Dehghani","year":"2025","journal-title":"Mol Neurobiol"},{"key":"2026060313352420500_ref26","doi-asserted-by":"publisher","first-page":"150633","DOI":"10.1016\/j.cej.2024.150633","article-title":"Novel nanocomposites improve functional recovery of spinal cord injury by regulating NF-\u03baB mediated microglia polarization","volume":"487","author":"Sun","year":"2024","journal-title":"Chem Eng J"},{"key":"2026060313352420500_ref27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12951-025-03528-2","article-title":"Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges","volume":"23","author":"Sanadgol","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"2026060313352420500_ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mco2.70386","article-title":"Exosome-based therapeutics: a natural solution to overcoming the blood\u2013brain barrier in neurodegenerative diseases","volume":"6","author":"Sun","year":"2025","journal-title":"MedComm"},{"key":"2026060313352420500_ref29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12033-021-00300-3","article-title":"Elucidating methods for isolation and quantification of exosomes: a review","volume":"63","author":"Kurian","year":"2021","journal-title":"Mol Biotechnol"},{"key":"2026060313352420500_ref30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/pharmaceutics17101336","article-title":"Exosome-based drug delivery: a next-generation platform for cancer, infection, neurological and immunological diseases, gene therapy and regenerative medicine","volume":"17","author":"Serrano","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref31","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/nano11061481","article-title":"Exosomes as naturally occurring vehicles for delivery of biopharmaceuticals: insights from drug delivery to clinical perspectives","volume":"11","author":"Butreddy","year":"2021","journal-title":"Nanomaterials"},{"key":"2026060313352420500_ref32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.69883\/jlkm.v1i1.3","article-title":"Hubungan Antara Kualitas Tidur, Beban Kerja Fisik Terhadap Perasaan Kelelahan Kerja pada Perawat Rawat Inap Kelas 3 Di RS PKU Muhammadiyah Gamping","volume":"1","author":"Luluk Wijanarti","year":"2022","journal-title":"J Lentera Kesehat Masy"},{"key":"2026060313352420500_ref33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.bioactmat.2025.09.048","article-title":"Learn from nature: biomimetic nanocarriers for intracellular protein delivery","volume":"55","author":"Zhu","year":"2026","journal-title":"Bioact Mater"},{"key":"2026060313352420500_ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioactmat.2024.04.007","article-title":"Hydrogel-exosome system in tissue engineering: a promising therapeutic strategy","volume":"38","author":"Fan","year":"2024","journal-title":"Bioact Mater"},{"key":"2026060313352420500_ref35","doi-asserted-by":"publisher","first-page":"10842","DOI":"10.3390\/ijms262210842","article-title":"Sub-15 nm nanoparticles for drug delivery: emerging frontiers and therapeutic potential","volume":"26","author":"De","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026060313352420500_ref36","doi-asserted-by":"publisher","first-page":"117248","DOI":"10.1016\/j.biopha.2024.117248","article-title":"Current knowledge of hybrid nanoplatforms composed of exosomes and organic\/inorganic nanoparticles for disease treatment and cell\/tissue imaging","volume":"178","author":"Soltanmohammadi","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2026060313352420500_ref37","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/pharmaceutics14081586","article-title":"Nanoparticles-based strategies to improve the delivery of therapeutic small interfering RNA in precision oncology","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref38","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/pharmaceutics17111502","article-title":"Nanoparticles used for the delivery of RNAi-based therapeutics","volume":"17","author":"Ren","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref39","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3390\/biomedicines13092167","article-title":"Intrathecal therapies for neurodegenerative diseases: a review of current approaches and the urgent need for advanced delivery systems","volume":"13","author":"Schreiner","year":"2025","journal-title":"Biomedicines"},{"key":"2026060313352420500_ref40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2174\/0118764029358553250325040749","article-title":"A comprehensive review on advancements in nanocarriers-based peptide delivery for cancer therapeutics","volume":"17","author":"Ali","year":"2025","journal-title":"Micro Nanosyst"},{"key":"2026060313352420500_ref41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.smaim.2022.07.005","article-title":"Nanotherapies from an oncologist doctor\u2019s view","volume":"4","author":"Liu","year":"2023","journal-title":"Smart Mater Med"},{"key":"2026060313352420500_ref42","doi-asserted-by":"publisher","first-page":"20234","DOI":"10.1021\/acsomega.3c01703","article-title":"Emergence of small interfering RNA-based gene drugs for various diseases","volume":"8","author":"Kurakula","year":"2023","journal-title":"ACS Omega"},{"key":"2026060313352420500_ref43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"key":"2026060313352420500_ref44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0115665232390238251121074917","article-title":"Revolutionizing drug and gene delivery: cutting-edge smart polymers for precision release","volume":"26","author":"Singh","year":"2025","journal-title":"Curr Gene Ther"},{"key":"2026060313352420500_ref45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202303597","article-title":"Stimuli-responsive nanotechnology for RNA delivery","volume":"10","author":"Zhou","year":"2023","journal-title":"Adv Sci"},{"key":"2026060313352420500_ref46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/pharmaceutics17060706","article-title":"Crossing the blood\u2013brain barrier: innovations in receptor- and transporter-mediated transcytosis strategies","volume":"17","author":"Ding","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref47","doi-asserted-by":"publisher","first-page":"100010","DOI":"10.1016\/j.preme.2024.100010","article-title":"Overcoming biological barriers: precision engineered extracellular vesicles for personalized neuromedicine","volume":"1","author":"Ravichandiran","year":"2024","journal-title":"Precis Med Eng"},{"key":"2026060313352420500_ref48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0122103031400035251014115919","article-title":"Emerging trends in magnetic nanoparticle delivery, synthesis and applications in biomedicine","volume":"16","author":"Jahan","year":"2025","journal-title":"Drug Deliv Lett"},{"key":"2026060313352420500_ref49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2024.1393646","article-title":"Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review","volume":"15","author":"Motamedi","year":"2024","journal-title":"Front Microbiol"},{"key":"2026060313352420500_ref50","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa de Almeida","year":"2021","journal-title":"Chem Soc Rev"},{"key":"2026060313352420500_ref51","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.2174\/1570159X19666210402104054","article-title":"siRNA therapeutics: future promise for neurodegenerative diseases","volume":"19","author":"Amiri","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"2026060313352420500_ref52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2024.1347987","article-title":"The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets","volume":"16","author":"Adamu","year":"2024","journal-title":"Front Aging Neurosci"},{"key":"2026060313352420500_ref53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00356","article-title":"Modeling Parkinson\u2019s disease with the alpha-synuclein protein","volume":"11","author":"G\u00f3mez-Benito","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026060313352420500_ref54","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","article-title":"Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026060313352420500_ref55","doi-asserted-by":"publisher","first-page":"e69450","DOI":"10.7759\/cureus.69450","article-title":"A review on the role of SNCA gene in neurodegenerative diseases","volume":"16","author":"Jahabardeen","year":"2024","journal-title":"Cureus"},{"key":"2026060313352420500_ref56","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.3390\/jcm13237243","article-title":"Alpha-synuclein and microglia in Parkinson\u2019s disease: from pathogenesis to therapeutic prospects","volume":"13","author":"Eo","year":"2024","journal-title":"J Clin Med"},{"key":"2026060313352420500_ref57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/JPD-181471","article-title":"A proposed roadmap for Parkinson\u2019s disease proof of concept clinical trials investigating compounds targeting alpha-synuclein","volume":"9","author":"Merchant","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"2026060313352420500_ref58","doi-asserted-by":"publisher","first-page":"11015","DOI":"10.2147\/IJN.S549893","article-title":"Nanotechnology for neurodegenerative diseases: recent progress in brain-targeted delivery, stimuli-responsive platforms, and organelle-specific therapeutics","volume":"20","author":"Gao","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"2026060313352420500_ref59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.1034072","article-title":"miRNA and antisense oligonucleotide-based \u03b1-synuclein targeting as disease-modifying therapeutics in Parkinson\u2019s disease","volume":"13","author":"Suvarna","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026060313352420500_ref60","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2026060313352420500_ref61","doi-asserted-by":"publisher","first-page":"102301","DOI":"10.1016\/j.mtbio.2025.102301","article-title":"Nanotechnology-driven strategies for gene therapy of arthritis","volume":"35","author":"Wang","year":"2025","journal-title":"Mater Today Bio"},{"key":"2026060313352420500_ref62","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/pharmaceutics14071344","article-title":"Nanotechnology-based siRNA delivery systems to overcome tumor immune evasion in cancer immunotherapy","volume":"14","author":"Deng","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref63","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026060313352420500_ref64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fragi.2023.1231706","article-title":"The dual face of microglia (M1\/M2) as a potential target in the protective effect of nutraceuticals against neurodegenerative diseases","volume":"4","author":"Darwish","year":"2023","journal-title":"Front Aging"},{"key":"2026060313352420500_ref65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2022.852003","article-title":"Alpha-synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies","volume":"13","author":"Menon","year":"2022","journal-title":"Front Neurol"},{"key":"2026060313352420500_ref66","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/pharmaceutics17111407","article-title":"Research progress on nasal delivery of siRNA nanocarrier systems for the treatment of neurodegenerative diseases","volume":"17","author":"Huang","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref67","doi-asserted-by":"publisher","first-page":"20220359","DOI":"10.1515\/tnsci-2022-0359","article-title":"Lipid-based nanoparticles for drug delivery in Parkinson\u2019s disease","volume":"15","author":"Cai","year":"2024","journal-title":"Transl Neurosci"},{"key":"2026060313352420500_ref68","doi-asserted-by":"publisher","first-page":"17802","DOI":"10.1021\/acsnano.2c08774","article-title":"Exosomes\u2013nature\u2019s lipid nanoparticles, a rising star in drug delivery and diagnostics","volume":"16","author":"Tenchov","year":"2022","journal-title":"ACS Nano"},{"key":"2026060313352420500_ref69","doi-asserted-by":"publisher","first-page":"104404","DOI":"10.1016\/j.jddst.2023.104404","article-title":"Pharmacokinetics and tumor delivery of nanoparticles","volume":"83","author":"Yuan","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"2026060313352420500_ref70","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"J Nanobiotechnology"},{"key":"2026060313352420500_ref71","doi-asserted-by":"publisher","first-page":"121803","DOI":"10.1016\/j.indcrop.2025.121803","article-title":"Nanotherapeutic formulations of enzyme inhibitors targeting cancer and neuroinflammation: an updated review","volume":"236","author":"Liu","year":"2025","journal-title":"Ind Crop Prod"},{"key":"2026060313352420500_ref72","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1007\/s13346-025-01815-x","article-title":"Preclinical testing of antiviral siRNA therapeutics delivered in lipid nanoparticles in animal models\u2014a comprehensive review","volume":"15","author":"Idres","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"2026060313352420500_ref73","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2174\/0122117385319695240911115239","article-title":"Chromatography and spectroscopic characterization of nano-carrier pharmaceuticals","volume":"14","author":"Shamim, Ali","year":"2024","journal-title":"Pharm Nanotechnol"},{"key":"2026060313352420500_ref74","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.2147\/IJN.S531558","article-title":"Application of biomimetic cell membrane-coated nanocarriers in cardiovascular diseases","volume":"20","author":"Zhao","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"2026060313352420500_ref75","doi-asserted-by":"publisher","first-page":"100991","DOI":"10.1016\/j.mam.2021.100991","article-title":"Strategies to deliver RNA by nanoparticles for therapeutic potential","volume":"83","author":"Cox","year":"2022","journal-title":"Mol Asp Med"},{"key":"2026060313352420500_ref76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/anbr.202400012","article-title":"Cell membrane-coated nanoparticles: a new frontier in immunomodulation","volume":"4","author":"Desai","year":"2024","journal-title":"Adv NanoBiomed Res"},{"key":"2026060313352420500_ref77","doi-asserted-by":"publisher","first-page":"102005","DOI":"10.1016\/j.cocis.2026.102005","article-title":"Nanoprecipitation- and nanoemulsification-based systems for efficient nucleic acid delivery","volume":"83","author":"Xenakis","year":"2026","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"2026060313352420500_ref78","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202100402","article-title":"Nanotechnology-assisted RNA delivery: from nucleic acid therapeutics to COVID-19 vaccines","volume":"5","author":"Rinoldi","year":"2021","journal-title":"Small Methods"},{"key":"2026060313352420500_ref79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctarc.2026.101166","article-title":"Cancer treatment and research communications nanovaccines in cancer immunoprevention and immunotherapy: current insights and future directions","volume":"47","author":"Ejim","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"2026060313352420500_ref80","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00702-023-02635-4","article-title":"The heterogeneity of Parkinson\u2019s disease","volume":"130","author":"W\u00fcllner","year":"2023","journal-title":"J Neural Transm"},{"key":"2026060313352420500_ref81","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/pharmaceutics12040350","article-title":"Steering the clinical translation of delivery systems for drugs and health products","volume":"12","author":"Pignatello","year":"2020","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41531-022-00313-y","article-title":"Lipid level alteration in human and cellular models of alpha synuclein mutations","volume":"8","author":"Avisar","year":"2022","journal-title":"npj Park Dis"},{"key":"2026060313352420500_ref83","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41531-025-01081-1","article-title":"Revamping Parkinson\u2019s disease therapy using PLGA-based drug delivery systems","volume":"11","author":"Lababidi","year":"2025","journal-title":"npj Park Dis"},{"key":"2026060313352420500_ref84","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.920989","article-title":"A mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson disease shows that 2-aminoquinoline targets JNK phosphorylation","volume":"26","author":"Zhu","year":"2020","journal-title":"Med Sci Monit"},{"key":"2026060313352420500_ref85","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3390\/biomedicines11041187","article-title":"Potential for therapeutic-loaded exosomes to ameliorate the pathogenic effects of \u03b1-synuclein in Parkinson\u2019s disease","volume":"11","author":"Rademacher","year":"2023","journal-title":"Biomedicines"},{"key":"2026060313352420500_ref86","doi-asserted-by":"publisher","first-page":"102671","DOI":"10.1016\/j.omtn.2025.102671","article-title":"Nose-to-brain siRNA delivery by PEI\/PPI-based nanoparticles reduces \u03b1-synuclein expression in a Parkinson\u2019s disease mouse model","volume":"36","author":"Feja","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026060313352420500_ref87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/polym17212838","article-title":"Chitosan (nano)formulations as therapeutic tools for neurodegenerative diseases: a comprehensive review","volume":"17","author":"Gomes","year":"2025","journal-title":"Polymers (Basel)"},{"key":"2026060313352420500_ref88","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.3390\/molecules27175481","article-title":"Lipopolysaccharide-induced model of neuroinflammation: mechanisms of action, research application and future directions for its use","volume":"27","author":"Skrzypczak-Wiercioch","year":"2022","journal-title":"Molecules"},{"key":"2026060313352420500_ref89","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026060313352420500_ref90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.163359","article-title":"Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson\u2019s disease","volume":"9","author":"Pons-Espinal","year":"2024","journal-title":"JCI Insight"},{"key":"2026060313352420500_ref91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"2026060313352420500_ref92","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.3390\/nano12213908","article-title":"Diverse pathways of engineered nanoparticle-induced NLRP3 inflammasome activation","volume":"12","author":"Liao","year":"2022","journal-title":"Nanomaterials"},{"key":"2026060313352420500_ref93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cells10092271","article-title":"Inhibition of cellular and animal inflammatory disease models by NF-\u03baB inhibitor DHMEQ","volume":"10","author":"Ma","year":"2021","journal-title":"Cells"},{"key":"2026060313352420500_ref94","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/biomedicines13020486","article-title":"Notch1 siRNA and AMD3100 ameliorate metabolic dysfunction-associated steatotic liver disease","volume":"13","author":"Zhu","year":"2025","journal-title":"Biomedicines"},{"key":"2026060313352420500_ref95","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jconrel.2025.01.007","article-title":"Drug delivery strategy of hemostatic drugs for intracerebral hemorrhage","volume":"379","author":"An","year":"2025","journal-title":"J Control Release"},{"key":"2026060313352420500_ref96","doi-asserted-by":"publisher","first-page":"100460","DOI":"10.1016\/j.carpta.2024.100460","article-title":"Chitosan\u2014an alternative drug delivery approach for neurodegenerative diseases","volume":"7","author":"Iyer","year":"2024","journal-title":"Carbohydr Polym Technol Appl"},{"key":"2026060313352420500_ref97","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40035-022-00285-2","article-title":"LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson\u2019s disease","volume":"11","author":"Chang","year":"2022","journal-title":"Transl Neurodegener"},{"key":"2026060313352420500_ref98","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1080\/15548627.2022.2139080","article-title":"PINK1-PRKN mediated mitophagy: differences between in vitro and in vivo models","volume":"19","author":"Han","year":"2023","journal-title":"Autophagy"},{"key":"2026060313352420500_ref99","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41420-025-02845-7","article-title":"Parkinson\u2019s associated protein DJ-1 regulates intercellular communication via extracellular vesicles in oxidative stress","volume":"11","author":"Page","year":"2025","journal-title":"Cell Death Discov"},{"key":"2026060313352420500_ref100","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7324\/JAPS.2021.110203","article-title":"Neuroprotective potential of naringenin-loaded solid-lipid nanoparticles against rotenone-induced Parkinson\u2019s disease model","volume":"11","author":"Megala","year":"2020","journal-title":"J Appl Pharm Sci"},{"key":"2026060313352420500_ref101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2020.00444","article-title":"Inhibition of TLR4 induces M2 microglial polarization and provides neuroprotection via the NLRP3 inflammasome in Alzheimer\u2019s disease","volume":"14","author":"Cui","year":"2020","journal-title":"Front Neurosci"},{"key":"2026060313352420500_ref102","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154-155","author":"Yonezawa","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"2026060313352420500_ref103","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/pharmaceutics13040500","article-title":"PLGA nanoparticle-based formulations to cross the blood\u2013brain barrier for drug delivery: from R&D to cGMP","volume":"13","author":"Zhi","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref104","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.3390\/polym17223055","article-title":"Recent advances on chitosan-based nanoparticles for brain drug delivery","volume":"17","author":"Ezzaki","year":"2025","journal-title":"Polymers (Basel)"},{"key":"2026060313352420500_ref105","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.3390\/molecules25194489","article-title":"Dendrimers as modulators of brain cells","volume":"25","author":"Maysinger","year":"2020","journal-title":"Molecules"},{"key":"2026060313352420500_ref106","doi-asserted-by":"publisher","first-page":"115291","DOI":"10.1016\/j.addr.2024.115291","article-title":"Lipid nanoparticles for RNA delivery: self-assembling vs driven-assembling strategies","volume":"208","author":"Nele","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"2026060313352420500_ref107","doi-asserted-by":"publisher","first-page":"446","DOI":"10.34172\/apb.2023.056","article-title":"An overview of nanostructured lipid carriers and its application in drug delivery through different routes","volume":"13","author":"Khan","year":"2023","journal-title":"Adv Pharm Bull"},{"key":"2026060313352420500_ref108","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12951-025-03352-8","article-title":"Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies","volume":"23","author":"Mehdizadeh","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"2026060313352420500_ref109","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/pharmaceutics15020621","article-title":"Cell-membrane-coated nanoparticles for targeted drug delivery to the brain for the treatment of neurological diseases","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2024.1394713","article-title":"The human alpha7 nicotinic acetylcholine receptor is a host target for the rabies virus glycoprotein","volume":"14","author":"O\u2019Brien","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"2026060313352420500_ref111","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/pharmaceutics14102237","article-title":"Blood\u2013brain barrier transport of transferrin receptor-targeted nanoparticles","volume":"14","author":"Thomsen","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref112","doi-asserted-by":"publisher","first-page":"100575","DOI":"10.1016\/j.ijpddr.2024.100575","article-title":"Lactoferrin-modified nanoemulsions enhance brain-targeting and therapeutic efficacy of arctigenin against Toxoplasma gondii-induced neuronal injury","volume":"27","author":"Lu","year":"2025","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2026060313352420500_ref113","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/pharmaceutics16020255","article-title":"Review of advances in coating and functionalization of gold nanoparticles: from theory to biomedical application","volume":"16","author":"Arcos Rosero","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref114","doi-asserted-by":"publisher","first-page":"114822","DOI":"10.1016\/j.addr.2023.114822","article-title":"Magnetic iron oxide nanoparticles for brain imaging and drug delivery","volume":"197","author":"Qiao","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"2026060313352420500_ref115","doi-asserted-by":"publisher","first-page":"101631","DOI":"10.1016\/j.apmt.2022.101631","article-title":"On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles","volume":"29","author":"Formica","year":"2022","journal-title":"Appl Mater Today"},{"key":"2026060313352420500_ref116","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/pharmaceutics13081291","article-title":"Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform\u2014a comprehensive review of their properties, preparation methods, and therapeutic applications","volume":"13","author":"Sivadasan","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref117","doi-asserted-by":"publisher","first-page":"103063","DOI":"10.1016\/j.mtchem.2025.103063","article-title":"Smart pH-responsive polymers in biomedical applications: nanoparticles, hydrogels, and emerging hybrid platforms","volume":"49","author":"Nunziata","year":"2025","journal-title":"Mater Today Chem"},{"key":"2026060313352420500_ref118","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12951-024-02859-w","article-title":"Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review","volume":"22","author":"Meng","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"2026060313352420500_ref119","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/pharmaceutics15071999","article-title":"Cell-penetrating and targeted peptides delivery systems as potential pharmaceutical carriers for enhanced delivery across the blood\u2013brain barrier (BBB)","volume":"15","author":"Ghorai","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026060313352420500_ref120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2024.1329636","article-title":"GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs","volume":"15","author":"Ji","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026060313352420500_ref121","doi-asserted-by":"publisher","first-page":"e70025","DOI":"10.1002\/wnan.70025","article-title":"Emerging biomimetic drug delivery nanoparticles inspired by extracellular vesicles","volume":"17","author":"Sundaram","year":"2025","journal-title":"WIREs Nanomed Nanobiotechnol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/6\/rgag052\/68462353\/rgag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/6\/rgag052\/68462353\/rgag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:35:27Z","timestamp":1780508127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgag052\/8700869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":121,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgag052","relation":{},"ISSN":["2042-7158"],"issn-type":[{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"rgag052"}}